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Abstract 
Background: People with granulomatosis with polyangiitis (GPA) commonly 
describe long delays before diagnosis. 
Aim: To study the natural history of GPA prior to diagnosis using primary care 
data, and determine whether clinical features could be identified to help earlier 
diagnosis. 
Design: Case-control study using the Clinical Practice Research Datalink. 
Methods: We compared primary care activity and clinical features between 
cases and 10 matched controls. 
Results: We identified 757 cases and matched 7,546 controls. Compared to 
controls, cases had more GP consultations and overall healthcare activity in the 
five years prior to their diagnosis, with a marked increase in the year before 
diagnosis, and particularly in the last 3 months. However, consultations were 
mostly for symptoms that were not specifically related to GPA. In the year prior 
to diagnosis, the most frequent and strongly predictive clinical features of GPA 
were Ear Nose and Throat (ENT) symptoms (34.5% of cases, odds ratio (OR) 
10.5, 95% confidence intervals (CI) 8.6-12.7), and general (constitutional) 
symptoms (21.5% of cases, OR 9.0, 95% CI 7.1-11.3). In the year before 
diagnosis a larger number of cases attended secondary care (382, 50.5%) than 
had records of clinical features of GPA. 
Conclusions: After discussing our findings, we conclude it would be difficult to 
identify cases of GPA earlier in primary care. Our results support a need for 
heightened awareness of this condition among secondary care clinicians, 
especially those assessing emergency admissions, and in the clinics which were 
most frequently attended by cases 3-12 months prior to diagnosis. 
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Introduction 
Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s 
Granulomatosis is the commonest life-threatening vasculitis in adults(1). It most 
commonly presents from the 6th decade onwards with ENT, lung, and/or renal 
involvement. In 80% of cases it is associated with finding anti-neutrophil 
cytoplasmic antibodies in serum. 20% of people die within one year of diagnosis, 
20% of survivors require renal replacement therapy, and the extent of organ 
involvement at diagnosis is an important predictor of long-term outcome(2,3). 
A survey of members of the patient support group Vasculitis UK reported 
diagnostic delay of >1 year in 22.9% of patients, the frustration of repeated 
primary care consultations and a “pinball” experience of attending several 
secondary care specialties before the condition was finally recognised(4). 
Shortening this diagnostic odyssey may lead to earlier treatment with potentially 
better outcomes. 
Routinely collected primary care data in the UK provides an opportunity to study 
healthcare activity prior to a diagnosis of GPA. We used the Clinical Practice 
Research Datalink (CPRD), to study the natural history of GPA prior to diagnosis 
using primary care data, and determine whether clinical features could be 
identified to help earlier diagnosis. 
Methods 
Source of data 
We used data from the Clinical Practice Research Datalink (CPRD), which is one 
of the largest databases of longitudinal medical records from primary care. It 
contains anonymized healthcare records from more than 13 million people and 
represents 8% of the UK population. CPRD participants are representative of the 
UK general population in terms of age, sex and ethnicity(5). CPRD records 
contain diagnostic and clinical information coded using Read codes (6), as well 
as prescriptions, and details of specialist referrals . We followed the CPRD’s 
recommendations for selecting research quality patient records and periods of 
quality data recording by including people contributing acceptable quality data in 
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up to standard practices. We used data from all 684 general practices 
contributing data to CPRD up to January 2015. 
Study participants and study design. 
We included all incident cases of GPA diagnosed between 1 Jan 1990 and 31 Dec 
2014, identified as previously described (7). Briefly, cases were included if they 
had a first diagnosis of GPA coded in the CPRD or linked Hospital Episode 
Statistics records; and at least one year of disease-free active follow up in the 
CPRD prior to their first code for GPA or vasculitis to exclude prevalent cases. Up 
to ten controls were randomly selected for each case, matched on GP practice, 
sex and within 5-years of age. All controls had to be alive and contributing data 
to the CPRD continuously for at least one year up to the diagnosis date of their 
matched case. The diagnosis date of cases, and the diagnosis date of the 
matched controls for each is the index date. 
Exposures 
Quantification of healthcare activity 
We counted the number of records of healthcare activity recorded for cases and 
controls in the 5 years prior to the index date. This included records of health 
promotion and administration (e.g. BP measurement, administration, and 
medication review), GP delivering healthcare (e.g. consultations, investigations 
and medication requests) and secondary care activity recorded in primary care 
(e.g. letters from secondary care, and records of attendance at hospital clinics). 
In addition we counted separately records of GP consultations, records of 
secondary care activity (hospital clinic appointments, A&E attendances and 
hospital admissions) and records of attendance at each hospital specialty clinic. 
If a patient had more than one consultation record in primary care or secondary 
care on the same day, we assumed this represented only one activity in order to 
reduce the chance of duplicate records(8). We excluded records on the index 
date, to exclude the appointment or hospital admission when the diagnosis was 
made. For secondary care activity, we conducted a sensitivity analysis excluding 
the last 3 months before the index date, to exclude secondary care activity 
directly linked with the diagnostic episode, because of reported delays of up to 3 
months for diagnoses made in secondary care being recorded in CPRD (9,10). 
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Clinical Features 
We counted the number of times cases and controls consulted their GP with 
clinical features that we considered suggestive of GPA before the index date. We 
included seven groups as shown in table 1. General (constitutional) symptoms, 
cutaneous, eye, ear nose and throat (ENT), renal, and ‘other’ clinical features 
were selected from the American College of Rheumatology (ACR) classification 
criteria for GPA (11), and version 3 of the Birmingham vasculitis activity score 
(BVAS) (12). We additionally included a respiratory group of cough and 
shortness of breath, rather than the specific imaging results included in the ACR 
classification criteria or BVAS score, because these imaging results were not 
available in our dataset. We included one control event, road traffic accident, 
which we expected to be recorded with similar frequency between cases and 
controls. 
Code lists 
Lists of Read codes for each clinical feature, and secondary care activity were 
compiled by searching the description fields of the Read code dictionary using a 
list of keywords and synonyms and excluding irrelevant codes, using a method 
described by Dave and Petersen(13). Where possible the resulting code lists 
were cross-referenced with published code lists available at an online clinical 
codes repository(14). Full lists of codes are available on request. 
Descriptive and statistical analysis of clinical features and healthcare activity 
Firstly, we plotted frequency histograms of the total number of GP consultations, 
records of healthcare activity, and consultations for each clinical feature in 5 
years before the index date for cases and 1 randomly selected control. 
Consultations increased markedly in the year before cases were diagnosed, 
therefore the following quantitative analysis reports the year before the index 
date. 
We grouped the number of GP and secondary care consultations/admissions, 
and all records of healthcare activity into exposure categories, and compared 
these between cases and all controls using conditional logistic regression. We 
also compared attendance at hospital specialty clinics, A&E and hospital 
admissions by calculating a ratio of frequency of attendance in cases and 
controls. We compared cases and controls who had at least one record for each 
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clinical feature, and calculated odds ratios (ORs) using conditional logistic 
regression. Statistical analysis was performed using Stata version 14 (Statacorp, 
College Station, TX, USA). 
Ethics 
Independent Scientific Advisory Committee (ISAC) for MHRA Database Research 
approval was obtained for this study (protocol 15_150R). 
Reporting guidelines 
This study is reported following the RECORD guidelines(15), which are an 
extension of STROBE(16), designed specifically for reporting studies conducted 
using observational routinely collected healthcare data.  
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Results 
We identified 757 cases of GPA and matched 7,546 controls. The baseline 
characteristics of cases and controls were similar: median age (interquartile 
range) at the index date was 61 (50-70) years in cases and 61 (50-71) years in 
controls, and 44.7% of both cases and controls were female. 
Quantification of healthcare activity 
Cases had a greater number of GP consultations and overall healthcare activity 
throughout the 5 years prior to diagnosis, with a marked increase in the 1 year 
prior to their index date (figure 1 & supplementary figure 1). In the year before 
the index date, twenty or more GP consultations were recorded in 157 (20.7%) 
of cases and 435 (5.8%) of controls; 30 or more records of healthcare activity 
were recorded in 314 (41.5%) of cases compared to 1,144 (15.2%) of controls 
(table 2). The greatest risks were conferred by ≥30 records of healthcare 
activity (OR 46.3, 95% CI 31.9-67.2), ≥20 GP consultations (OR 32.1, 95% CI 
23.4-44.1), and attending ≥4 different specialty clinics (OR 22.6, 95% CI 13.4-
38.0). Cases were 3 times more likely than controls to have records of hospital 
clinic attendances, with Rheumatology, ENT, Ophthalmology, Respiratory and 
Renal being the 5 most frequently-attended specialties by cases in the year 
before the index date. ENT, Ophthalmology, Rheumatology, Gastroenterology 
and Urology were the most frequently attended specialties when the last 3 
months before the index date were excluded (table 3). 35% of cases had a 
record of ≥1 hospital clinic appointment. 382 (50.5%) of cases had ≥1 contact 
with secondary care (twice as likely as controls), and were 3 times more likely to 
attend A&E and 4 times more likely to have an inpatient admission (table 3). 
Excluding secondary care activity in the 3 months before diagnosis, the ratios 
were reduced but cases remained more likely than controls to have each type of 
contact with secondary care (table 3).  
Clinical features recorded before diagnosis 
The number of consultations for the ENT, respiratory, and general 
(constitutional) groups of clinical features were elevated in cases compared to 
controls throughout the five years prior to their index date, with a notable 
increase in the final year (figure 1). Consultations for the other groups of clinical 
features also visibly increased in cases in the final year (supplementary data for 
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review). In the year before their index date, both the percentage of people 
affected by each clinical feature, and OR were elevated for cases compared to 
controls in all clinical features, however each clinical feature was recorded in a 
minority of cases (table 4). Of the individual clinical features, vasculitic rash 
conferred the highest risk of diagnosis of GPA (OR 30.3, 95% CI 3.1-288.4), but 
affected only 0.4% of cases. The groups of ENT and general (constitutional) 
symptoms were both the most frequent features occurring in 34.5% and 21.5% 
of cases respectively and conferred the second and third highest increased risk 
of future development of GPA, (OR 10.5, 95% CI 8.6-12.7 and OR 9.0, 95% CI 
7.1-11.3 respectively). There was no increase in risk of road traffic accident (our 
control code) among cases compared to controls (OR 0.9, 95% CI 0.5-1.8). 
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Discussion 
Summary of results and interpretation 
This is the first study to provide evidence of increased GP and secondary care 
consultations in the pre-diagnostic period of GPA. Consultations among cases 
increased markedly in the year before diagnosis, and particularly in the final 3 
months, but they were frequently for non-specific symptoms. The strongest 
predictor of a diagnosis of GPA was an increase in healthcare activity: ≥30 
records of healthcare activity within a year, including records about health 
promotion and administration, GPs delivering healthcare, and secondary care 
activity recorded in primary care. 
Strengths and limitations 
The main strengths of this study are that it was performed in the largest 
available database of primary care records, and included a large number of 757 
people prior to their diagnosis with GPA. Another strength is that using a 
prospectively collected database minimises recall bias. The main limitations of 
this study are common to all observational studies in healthcare databases. The 
quality of outcome data is likely to be incomplete for coding of symptoms and 
secondary care activity. This would affect both cases and controls non-
differentially, meaning our estimates are likely to be conservative. We attempted 
to quantify the impact of ascertainment bias in our study by use of a control 
code, and found no evidence for it, in that our control code of road traffic 
accident was marginally less common in cases than in controls. It would have 
been interesting to replicate the study in the other main sub-type of ANCA-
associated vasculitis, microscopic polyangiitis. However, this is a more recently 
defined disease, and under the Read code system was not coded as a specific 
subtype of vasculitis until 2009, and at this time there were not enough cases to 
study. 
How our results fit in with the literature 
There are few previous studies of the pre-diagnostic period in GPA, and our 
report is the first to our knowledge of pre-diagnostic consultations. However, 
length of delay between onset of symptoms and diagnosis has previously been 
reported. Delay between first symptoms of ANCA-associated vasculitis and 
diagnosis was found to be median 2.6 (interquartile range 1.2-5.2) months from 
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retrospective case note review in a multi-region audit including 130 patients 
newly diagnosed with ANCA-associated vasculitis in 2013-2014(17). This is 
similar to the diagnostic delay of median 2 months reported in Sweden 1997-
2006 (18) and median 4 months in Finland 1996-2000(19). These studies used 
data collected from doctor’s notes which may be limited by selective recording. 
The Vasculitis UK member’s survey of 314 respondents with GPA, reported 
longer diagnostic delay. 35.7% reported delay between symptom onset and 
diagnosis of more than 6 months, and 22.9% reported delay of greater than 1 
year (4). This study was retrospective, with the limitation of recall bias, however 
the results are more in keeping with our study’s findings. 
Our study shows evidence of increased health-seeking behaviour recorded in the 
primary care record for several years before diagnosis, supporting the odyssey 
of being unwell for a long time without a diagnosis. And our study shows that 
attendance at ≥4 different specialist clinics is strongly associated with a 
diagnosis of GPA, and that the 5 most commonly attended clinics were ENT, 
Ophthalmology, Rheumatology, Gastroenterology and Urology. This supports the 
description made by patient charities of delays before recognition of the 
diagnosis after contact with secondary care and the “pinball” experience of some 
people who attend multiple medical specialities before receiving a diagnosis. 
Clinical implications 
Because electronic algorithms to alert GPs to consider rare disease diagnoses are 
an aspiration of the UK Strategy for Rare Diseases (20), we considered whether 
to develop a predictive tool to aid earlier diagnosis in GPA. Predictive models 
have been recommended by the National Institute for Health and Care 
Excellence (NICE) for use in UK primary care to predict risk of cardiovascular 
disease(21) and fragility fractures(22), and have been incorporated into one 
primary care software system to predict risk of cancer(23). 
However, the crucial consideration in prediction of rare disease is that the 
prevalence of the disease in the population being tested affects the predictive 
value of a model or test. The rarer the disease the lower the positive predictive 
value (PPV) of a test (i.e. the probability that an individual actually has the 
disease if the prediction tool flags them as ‘at risk’). The conditions in which risk 
prediction tools are currently used are much more common than GPA: 
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cardiovascular disease affects ~3% of the population(24), osteoporosis 
~2%(22) and cancers ~0.9%(25), compared to and 0.0013% for GPA(7). If we 
compare simple predictive models (that flag people as ‘high risk’ or not), that all 
have a sensitivity of 100% and a specificity of 90%, they would have different 
PPVs in different diseases. For cardiovascular disease 31% of people flagged as 
‘at risk’ would have cardiovascular disease, for osteoporosis 20% of people 
flagged as ‘at risk’ would have osteoporosis, for cancers 8.6% of people flagged 
as ‘at risk’ would have cancer, and for GPA only 1 of every 10,000 people 
flagged as ‘at risk’ would have GPA. This would create a large number of well 
people who would be flagged as ‘at risk’ in GPA.  
In addition, due to the low prevalence of any predictive features in cases of GPA, 
the combinations needed to build a model with a specificity as high as 90% 
would reduce the sensitivity, and such a model would only identify a small 
proportion of cases. We therefore decided that it would not be worthwhile to 
develop a risk prediction score. 
Conclusion 
Our study shows that people who are diagnosed with GPA had increased health 
seeking behaviour for several years before diagnosis, however it was difficult to 
identify them earlier in primary care data. Our results support a need for 
speedier diagnosis of this condition among secondary care clinicians, particularly 
amongst unselected acute medical admissions, and in the clinics which were the 
most frequently attended specialty clinics in the 3-12 months prior to diagnosis. 
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Table 1: Clinical features included in the study 
Clinical feature 
group 
Specific clinical features included Source 
General  Fever / sweats (fevers, pyrexia, rigors or night sweats 
without specified cause) 
BVAS 
 
Myalgia (aching muscles, muscle pain, muscular 
rheumatism without specified cause) 
BVAS 
 
Arthritis (arthritis or arthralgia without specified cause e.g. 
septic, rheumatoid) 
BVAS 
 
Weight loss (documented weight loss regardless of cause) BVAS 
Cutaneous Rash (any rash or purpura without specified cause)  
Specific rash (non-blanching rash or purpura only) BVAS 
Eye Eye (scleritis, episcleritis, uveitis, conjunctivitis, blepharitis, 
keratitis, or significant proptosis without specified cause 
e.g. infection) 
BVAS 
ENT 
 
Deafness (hearing difficulty, deafness, blocked ear, 
deteriorating hearing without specified cause) 
BVAS 
Ear (Otitis media, mastoiditis, earache, ear discharge 
unless malignant or congenital) 
BVAS 
Purulent or bloody nasal discharge or ulceration (nose 
bleed, epistaxis, nasal symptoms, nose symptoms, nasal 
discharge, nasal obstruction, nasal congestion) 
BVAS & ACR 
Hoarseness BVAS 
Subglottic stenosis BVAS 
Sinusitis (blocked sinuses, sinus pain, sinus infection) BVAS 
Chest Breathlessness  
Cough  
Renal 
 
Renal impairment (renal impairment, CKD, rise in 
creatinine without specified cause) 
BVAS 
Haemoproteinuria (haematuria or proteinuria without 
specified cause) 
BVAS & ACR 
‘Other’ 
 
Fatigue (fatigue, lethargy, malaise, asthenia, lassitude, 
tiredness, exhaustion, general weakness without specified 
cause, and excluding chronic fatigue) 
BVAS 
Control code Road traffic accident  
ACR: American College of Rheumatology 1990 classification criteria for granulomatosis with 
polyangiitis, BVAS: Birmingham vasculitis activity score (version 3). 
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Table 2: Records of consultations and healthcare activity in the year before the index date 
Type of 
consultation / 
Healthcare 
activity 
 All cases and controls 
Category Cases, n (%) 
N=757 
Controls, n 
(%) 
N=7,546 
Odds ratio (95% CI) P value 
No. of GP 
consultations 
0-4 103 (13.6%) 3,976 (52.7%) 1  
5-9 211 (27.9%) 1,874 (24.8%) 6.3 (4.8-8.1) <0.001 
10-14 168 (22.2%) 872 (11.6%) 12.5 (9.4-16.6) <0.001 
15-19 118 (16.6%) 389 (5.2%) 23.9 (17.3-33.0) <0.001 
20+ 157 (20.7%) 435 (5.8%) 32.1 (23.4-44.1) <0.001 
No. of records 
of healthcare 
activity 
0-4 51 (6.7%) 2,611 (34.6%) 1  
5-9 62 (8.2%) 1,275 (16.9%) 3.5 (2.4-5.2) <0.001 
10-14 85 (11.2%) 931 (12.3%) 8.3 (5.6-12.3) <0.001 
15-19 80 (10.6%) 688 (9.1%) 12.7 (8.5-18.9) <0.001 
20-24 94 (12.4%) 521 (6.9%) 21.5 (14.4-32.1) <0.001 
25-29 71 (9.4%) 376 (5.0%) 24.8 (16.2-38.0) <0.001 
30+ 314 (41.5%) 1,144 (15.2%) 46.3 (31.9-67.2) <0.001 
A&E 
attendances 
0 622 (82.2%) 7,152 (94.8%) 1  
1 76 (10.0%) 289 (3.8%) 3.8 (2.9-5.1) <0.001 
≥2 59 (7.8%) 105 (1.4%) 8.7 (6.0-12.5) <0.001 
Hospital 
admissions 
0 538 (71.1%) 7,031 (93.2%) 1  
1 110 (14.5%) 326 (4.3%) 6.2 (4.8-8.0) <0.001 
≥2 109 (14.4%) 189 (2.5%) 12.8 (9.4-17.4) <0.001 
Hospital clinic 
appointments 
0 490 (64.7%) 6,341 (84.1%) 1  
1 59 (7.8%) 484 (6.4%) 3.1 (2.2-4.2) <0.001 
≥2 208 (27.5%) 718 (9.5%) 8.6 (6.6-11.2) <0.001 
Number of 
different 
hospital 
specialty 
clinics 
attended 
0 490 (64.7%) 6,346 (84.1%) 1  
1 116 (15.3%) 784 (10.4%) 3.9 (3.0-5.1) <0.001 
2 76 (10.0%) 261 (3.5%) 8.9 (6.3-12.5) <0.001 
3 43 (5.7%) 105 (1.4%) 13.5 (8.8-20.7) <0.001 
≥4 32 (4.2%) 50 (0.7%) 22.6 (13.4-38.0) <0.001 
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Table 3: Secondary care activity in the year before the index date 
Type of secondary care 
activity 
Patients attending in the 1 year before 
diagnosis 
Sensitivity analysis: 3-12 months before 
diagnosis 
 
Cases 
(n=757) 
Controls 
(n=7,546) Ratio 
Cases 
(n=757) 
Controls 
(n=7,546) 
 
Ratio 
≥ 1 clinic appointment 265 (35.3%) 677 (9.0%) 4 179 (23.9%) 591 (7.9%) 3 
 
267 (35.3%) 
1,205 
(16.0%) 
2 179 (23.7%) 1,003 (13.3%) 2 
Rheumatology clinic 73 (9.6%) 62 (0.8%) 12 24 (3.2%) 50 (0.7%) 5 
ENT clinic 70 (9.2%) 102 (1.4%) 7 33 (4.4%) 79 (1.0%) 4 
Respiratory clinic 51 (6.7%) 66 (0.9%) 8 12 (1.6%) 39 (0.5%) 3 
Ophthalmology clinic 51 (6.7%) 202 (2.7%) 3 29 (3.8%) 151 (2.0%) 2 
Renal clinic 38 (5.0%) 20 (0.3%) 19 13 (1.7%) 15 (0.2%) 9 
General medical clinic 28 (3.8%) 56 (0.7%) 5 11 (1.5%) 34 (0.5%) 3 
Gastroenterology clinic 24 (3.2%) 93 (1.2%) 3 17 (2.2%) 65 (0.9%) 3 
Cardiac clinic 20 (2.6%) 112 (1.5%) 2 12 (1.6%) 84 (1.1%) 1 
Orthopaedic clinic 18 (2.4%) 224 (3.0%) 1 13 (1.7%) 172 (2.3%) 1 
General surgery clinic 17 (2.2%) 118 (1.6%) 1 11 (1.5%) 80 (1.1%) 1 
Urology clinic 17 (2.2%) 126 (1.7%) 1 14 (1.8%) 89 (1.2%) 2 
Dermatology clinic 14 (1.8%) 103 (1.4%) 1 10 (1.3%) 78 (1.0%) 1 
Haematology clinic 14 (1.8%) 31 (0.4%) 5 6 (0.8%) 21 (0.3%) 3 
Neurology clinic 12 (1.6%) 45 (0.6%) 3 8 (1.1%) 31 (0.3%) 3 
Gynaecology clinic 11 (1.5%) 57 (0.8%) 2 5 (0.7%) 30 (0.4%) 2 
Oncology clinic 8 (1.1%) 67 (0.9%) 1 4 (0.5%) 45 (0.6%) 1 
Other clinics attended by 
<1% of cases 
73 (9.6%) 376 (5.0%) 2 36 (4.8%) 271 (3.6%) 1 
≥ 1 A&E attendance 135 (17.8%) 394 (5.2%) 3 71 (9.4%) 303 (4.0%) 2 
≥ 1 Hospital admission 219 (28.9%) 515 (6.8%) 4 102 (13.5%) 387 (5.1%) 3 
≥ 1 secondary care 
contact 382 (50.5%) 
1,566 
(20.8%) 2 243 (32.1%) 1,309 (17.4%) 2 
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Table 4: Clinical features of vasculitis documented in the year before the index date 
Clinical Feature All cases and controls 
 Cases, n (%) 
N=757 
Controls, n 
(%) 
N=7,546 
Odds ratio (95% CI) P value 
Respiratory 221 (29.2%) 827 (11.0%) 3.6 (3.0-4.3) <0.0001 
Cough 165 (21.8%) 638 (8.5%) 3.1 (2.6-3.8) <0.0001 
Breathlessness 81 (10.7%) 279 (3.7) 3.5 (2.6-4.5) <0.0001 
Renal 81 (10.7%) 136 (1.8%) 8.7 (6.3-12.0) <0.0001 
Renal impairment 65 (8.6%) 93 (1.2%) 10.8 (7.3-15.8) <0.0001 
Haem/proteinuria 22 (2.9%) 45 (0.6%) 5.2 (3.1-8.9) <0.0001 
ENT 261 (34.5%) 381 (5.1%) 10.5 (8.6-12.7) <0.0001 
Sinus symptoms 127 (16.8%) 132 (1.8%) 11.5 (8.8-14.9) <0.0001 
Nasal bleeding / 
crusting 
93 (12.3%) 63 (0.8%) 17.0 (12.1-23.9) <0.0001 
Deafness 45 (5.9%) 109 (1.4%) 4.4 (3.0-6.2) <0.0001 
Ear symptoms 70 (9.3%) 69 (0.9%) 12.0 (8.4-17.1) <0.0001 
Hoarseness / SGS 11 (1.5%) 28 (0.4%) 4.0. (2.0-8.0) 0.0006 
Eye (Red eye) 73 (9.6%) 159 (2.1%) 5.1 (3.8-6.8) <0.0001 
General 163 (21.5%) 248 (3.3%) 9.0 (7.1-11.3) <0.0001 
Arthritis 100 (13.2%) 147 (2.0%) 8.4 (6.3-11.1) <0.0001 
Fever 22 (2.9%) 29 (0.4%) 8.6 (4.8-15.5) <0.0001 
Myalgia 33 (4.4%) 49 (0.7%) 7.4 (4.6-11.7) <0.0001 
Weight loss 22 (2.9%)) 33 (0.4%) 7.0 (4.0-12.2) <0.0001 
Other (Fatigue) 57 (7.5%) 147 (2.0%) 4.2 (3.1-5.8) <0.0001 
Cutaneous (Rash) 44 (5.8%) 231 (3.1%) 2.0 (1.4-2.8) 0.0002 
Vasculitic rash 3 (0.4%) 1 (0.01%) 30.0 (3.1-288.4) 0.0015 
RTA (control) 10 (1.3%) 109 (1.4%) 0.9 (0.5-1.8) 0.7856 
SGS = subglottic stenosis RTA=road traffic accident 
 
